Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Accured Expenses: 2013-2024

Historic Change in Accured Expenses for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$3.6 million.

  • Zevra Therapeutics' Change in Accured Expenses fell 137.93% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.0 million, marking a year-over-year decrease of 85.33%. This contributed to the annual value of -$3.6 million for FY2024, which is 132.33% down from last year.
  • Zevra Therapeutics' Change in Accured Expenses amounted to -$3.6 million in FY2024, which was down 132.33% from $11.1 million recorded in FY2023.
  • Zevra Therapeutics' Change in Accured Expenses' 5-year high stood at $11.1 million during FY2023, with a 5-year trough of -$3.6 million in FY2024.
  • In the last 3 years, Zevra Therapeutics' Change in Accured Expenses had a median value of $3.1 million in 2022 and averaged $3.6 million.
  • Per our database at Business Quant, Zevra Therapeutics' Change in Accured Expenses slumped by 219.55% in 2021 and then surged by 381.31% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Change in Accured Expenses stood at $931,000 in 2020, then crashed by 219.55% to -$1.1 million in 2021, then spiked by 381.31% to $3.1 million in 2022, then spiked by 255.48% to $11.1 million in 2023, then slumped by 132.33% to -$3.6 million in 2024.